Vera Therapeutics to Participate at Upcoming Investor Conferences
Vera Therapeutics (Nasdaq: VERA), a late clinical-stage biotechnology company developing treatments for immunological diseases, has announced its management team's participation in upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vera Therapeutics (Nasdaq: VERA), a late clinical-stage biotechnology company developing treatments for immunological diseases, has announced its management team's participation in upcoming investor conferences. The company will participate in two events:
1. The Guggenheim Securities Healthcare Innovation Conference on November 13, 2024, at 9:30am EST in Boston, MA, featuring a fireside chat and one-on-one meetings.
2. The 7th Annual Evercore ISI HealthCONx Conference on December 5, 2024, at 7:55am EST in Coral Gables, FL, also including a fireside chat and one-on-one meetings.
Webcasts will be available for both events with 90-day replay access through Vera's website.
Details
News Market Reaction – VERA
The recorded move for VERA in the trading session of this news was -1.94%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRISBANE, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present and participate in one-on-one meetings at upcoming investor conferences.
Investor Conference Details:
- Guggenheim Securities Healthcare Innovation Conference
Format: Fireside Chat and 1x1s
Webcast: https://wsw.com/webcast/guggen/vera/1942294
Date: Wednesday, November 13, 2024
Time: 9:30am EST
Location: Boston, MA
- 7th Annual Evercore ISI HealthCONx Conference
Format: Fireside Chat and 1x1s
Webcast: https://wsw.com/webcast/evercore44/vera/2364138
Date: Thursday, December 5, 2024
Time: 7:55am EST
Location: Coral Gables, FL
A replay of the webcast will be available for 90 days and can be accessed by visiting the “Investor Calendar” section of the Vera Therapeutics website.
About Vera
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. For more information, please visit www.veratx.com.
For more information, please contact:
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Madelin Hawtin
LifeSci Communications
MHawtin@lifescicomms.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.